ClinicalTrials.gg
Active, not recruitingNCT04542161NAC ME/CFSUpdated Jun 22, 2026

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

A Phase 2 interventional study of NAC 900mg/day and NAC 3600mg/day in Chronic Fatigue Syndrome and Myalgic Encephalomyelitis, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Weill Medical College of Cornell University · Phase 2, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.

Planned enrollment
17th of 58
95 · median 50
Started
2020
with 4 others
Phase 2
12 of 86
4 open now
Primary completion
2027-04
later than 10 of 23 live
Registered
54th of 86
by date

Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 17th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2020, is one of 12 in phase 2, reaches primary completion later than 10 of the 23 other live ones, and was the 54th registered.

Fatigue Syndrome, Chronic

265 studies on the registry are indexed under Fatigue Syndrome, Chronic; 63 are open to participants now.

Browse Fatigue Syndrome, Chronic studies →

Open to participants now

21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Fatigue Syndrome, Chronic studies recruiting now, 19 (42%) set no upper age limit and 20 (44%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Fatigue Syndrome, Chronic with a site in United States, or all of them as a file.
02

Study summary

Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained multisymptom/multisystem disorder for which there are currently no validated treatments. The present exploratory clinical trial aims to advance our understand of the mechanisms of in situ GSH synthesis control through assessment of the response of brain GSH and plasma markers of oxidative stress to different doses of NAC in comparison to placebo, as a potential treatment for ME/CFS that would provide neuroprotection against oxidative stress by restoring cortical GSH reserves. If successful, this exploratory clinical trial would address a significant public health concern by shedding new light onto the mechanisms of action of NAC in brain GSH restoration, which could open a new avenue for the development of potentially effective treatments for a disorder, ME/CFS, that currently has none.

Read the detailed description

This phase two, single-site study will utilize a double-blind, placebo-controlled, randomized, pre-/post-treatment design to investigate the effect of NAC dosing on brain GSH levels and measure temporally concordant plasma levels of several established circulating markers of oxidative stress. Three study groups, of 20 subjects each (for a total of 60 who completed all components of the study), will each be administered a different dose (0 mg/day, 900mg/day, 3600mg/day) of the study intervention over a four week period; N-acetylcysteine (NAC) treatment. Subjects receiving 0 mg/day dose will be administered a placebo. Baseline visit assessments will include blood collection, survey questionnaires, MRI and MRS imaging. Subjects whose initial screening confirms low GSH level at baseline will be provided with a 4-week supplement of anonymized NAC or placebo caplets. After 4 weeks, subjects will then undergo a follow-up visit to repeat the baseline assessments.

03

Conditions studied

  • Chronic Fatigue Syndrome
  • Myalgic Encephalomyelitis
04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, ages 21 to 60 years (inclusive).
  • Baseline GSH levels at or less than a predefined cutoff value.
  • Primary diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
  • Willing and capable of providing .

Exclusion criteria

Exclusion Criteria:

  • Significant and/or comorbid axis I (especially mood and anxiety) and axis II disorders.
  • Any significant neurological illness or impairment.
  • Other unstable medical conditions (asthma, hypertension, endocrine or metabolic disease, etc).
  • History alcohol abuse.
  • Positive urine toxicology at screening and on days of assessments.
  • Positive pregnancy test at screening or on days of assessments.
  • for clinical MRI scan (e.g., pacemaker, metallic prosthesis).
  • Baseline GSH levels higher than a predefined cutoff value.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (estimated)

Study arms

  • Active comparator
    NAC 900mg/day

    Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period

    Drug: NAC 900mg/day

  • Active comparator
    NAC 3600mg/day

    Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period

    Drug: NAC 3600mg/day

  • Placebo comparator
    NAC 0mg/day (Placebo)

    Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period

    Drug: NAC 0mg/day (Placebo)

Interventions

  • DrugNAC 900mg/day

    Drug page: AcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    self administer NAC 900mg/day caplets for a four week period

  • DrugNAC 3600mg/day

    Drug page: AcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    self administer NAC 3600mg/day caplets for a four week period

  • DrugNAC 0mg/day (Placebo)

    self administer NAC 0mg/day (placebo) caplets for a four week period

06

What researchers measure

Primary outcomes

  1. Change in GSH levels of treatment response: measure 1

    Levels of occipital cortex GSH, as measured in vivo with 1H MRS

    Time frame: pre/post 4 weeks of NAC supplementation

  2. Change in GSH levels of treatment response: measure 2

    Levels of striatal GSH, as measured in vivo with 1H MRS

    Time frame: pre/post 4 weeks of NAC supplementation

Secondary outcomes

  1. Change of levels of ventricular CSF lactate of treatment response

    Levels of ventricular CSF lactate, as measured in vivo with 1H MRS

    Time frame: pre/post 4 weeks of NAC supplementation

  2. Change of regional cerebral blood flow (rCBF) of treatment response

    Regional cerebral blood flow (rCBF), as measured in vivo with perfusion MRI

    Time frame: pre/post 4 weeks of NAC supplementation

  3. Change in Oxidative stress levels of treatment response: measure 1

    Level of F2-isoprostanes, a marker of oxidative stress, in plasma samples obtained

    Time frame: pre/post 4 weeks of NAC supplementation

  4. Change in Oxidative stress levels of treatment response: measure 2

    Level of 8-hydroxy-2-deoxy guanosine (8-OH-2dG), a DNA damage marker, in plasma samples obtained

    Time frame: pre/post 4 weeks of NAC supplementation

  5. Change in Oxidative stress levels of treatment response: measure 3

    Level of reduced (GSH) glutathione, an antioxidant capacity and redox state marker, in plasma obtained

    Time frame: pre/post 4 weeks of NAC supplementation

  6. Change in Oxidative stress levels of treatment response: measure 4

    Level of oxidized (GSSG) glutathione, an antioxidant capacity and redox state marker, in plasma obtained

    Time frame: pre/post 4 weeks of NAC supplementation

  7. Change in Oxidative stress levels of treatment response: measure 5

    Level of GSH peroxidase, an antioxidant enzyme activity marker, in plasma obtained

    Time frame: pre/post 4 weeks of NAC supplementation

  8. Change in Oxidative stress levels of treatment response: measure 6

    Level of protein carbonyls, a protein damage marker, in plasma obtained

    Time frame: pre/post 4 weeks of NAC supplementation

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Apr 2027, 79 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Sep 9, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04542161
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Sep 1, 2020
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Dikoma C. Shungu, Ph.D.
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion